FDA Inspection
Novartis Pharma AGNovartis Pharma AG – FDA Inspection, Jul 6, 2017
Record Details
This FDA Inspection record concerns Novartis Pharma AG, with an inspection on July 6, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
- Omotunde O. Osunsanmi (Issuing Officer)
View Company Profile
ID · 25132932-baad-4786-893f-6aa8f8fa697b
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1021086
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Novartis Pharma AG
10| Date | Classification | Office | Project area |
|---|---|---|---|
| August 30, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 29, 2019 | Not classified | Office of Inspections and Investigations | |
| July 12, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 20, 2018 | Not classified | Office of Inspections and Investigations | |
| January 14, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Novartis Pharma AG
- FDA Inspection 1180833 - 2022-08-30
- FDA Inspection 1109986 - 2019-08-29
- FDA Inspection 1099919 - 2019-07-12
- FDA Inspection 1053787 - 2018-04-20
- FDA Inspection 916149 - 2015-01-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.